Bioprocessing Applications

Scalable solutions for diverse modalities and applications

Thermo Fisher Scientific strives to advance productivity across bioprocessing workflows to help accelerate development, increase product yield, and facilitate sustainability. Our scalable, connected solutions enable consistency and efficiency as programs move from early-stage development to production. Designed to reduce risk and maximize resource use, our portfolio is designed to support quick, dependable outcomes across modalities from antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to cell and gene therapies, messenger RNA (mRNA), and vaccines.
 

Antibody-drug conjugates (ADCs)

Integrated bioprocessing solutions aim to simplify ADC development and facilitate productivity and reliability from research to manufacturing.

Cell Therapy

Automation-ready systems designed to connect cell therapy processes, helping to maintain product integrity while optimizing efficiency from bench to bedside.

Gene Therapy

Modular, scalable solutions help gene therapy developers achieve consistent quality and easy scale-up, contributing to risk reduction across workflows.

Monoclonal antibodies (mAbs)

Our advanced portfolio supports high-yield, scalable mAb production with robust process control, helping reduce manufacturing risk.

Messenger RNA (mRNA)

Innovative technologies support rapid development cycles and manufacturing, allowing reliable delivery of high-quality mRNA therapy.

Vaccines

Connected workflows are built to accelerate vaccine development, driving consistency and sustainability to help meet global health demands efficiently.


Frequently asked questions

Bioprocessing plays a critical role in therapeutic development by supporting the efficient production, purification, and formulation of biologics such as monoclonal antibodies, cell and gene therapies, and vaccines. It helps maintain product quality, consistency, and scalability from early research through commercial manufacturing, bringing effective therapies to patients faster.

Our bioprocessing solutions support workflows from early process development through commercial manufacturing. Solutions include upstream systems for cell culture and expansion, downstream purification, and analytical tools for product safety, potency, and quality control. Each solution is designed to improve productivity, consistency, and speed across modalities, such as ADCs, cell and gene therapies, mAbs, mRNA, and vaccines.

Bioprocessing in early preclinical development focuses on flexibility, speed, and scalability to rapidly evaluate candidates and optimize small-scale processes. In contrast, commercial manufacturing emphasizes consistency, compliance, and efficiency at a large scale to allow reliable, high-yield production that meets regulatory standards. Bridging the gap between these stages requires scalable, connected solutions that support easy process transfer and reduce risk during scale-up.

Scaling introduces challenges such as maintaining yield and quality across volumes, securing the supply of raw materials, and aligning with CGMP and regulatory standards. Addressing these factors early supports consistent performance and helps minimize risk during scale-up.

We collaborate with organizations across biotech, biopharma, and CDMOs to align bioprocessing solutions with project goals. Our global network offers technical experience and regulatory insights to help advance programs from early development to large-scale manufacturing. By connecting products, services, and scientific support, we help reduce risk and accelerate progress toward clinical and commercial milestones.

Article: Innovative Downstream Purification Solutions for Viral Vectors.

Poster: Advantage of Antibody-Based Selectivity in the Purification of Biologics.

Poster: Downstream Purification Solutions for Viral Vectors.

White paper: Introduction to Mass Transfer in Single-Use Bioreactors.